SynthesisHepatology communications2025
Portal cavernoma cholangiopathy: A systematic review of current understanding, clinical significance, and management.
Synthesis in Hepatology communications, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- [Advances in the diagnosis and treatment of portal hypertensive gastrointestinal and bile duct disease].Zhonghua gan zang bing za zhi = Zhonghua ganzangbing zazhi = Chinese journal of hepatology · 2026Review
- Endovascular management of extrahepatic portal vein obstruction (EHPVO): expanding beyond surgical shunts.Abdominal radiology (New York) · 2026Review
- Management of periampullary variceal bleeding with a biliary stent and endoscopic ultrasound-guided cyanoacrylate injection.Endoscopy · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Portal cavernoma cholangiopathy (PCC) is a rare condition characterized by abnormalities of the intrahepatic and extrahepatic bile ducts and the gallbladder, resulting from long-standing chronic portal vein thrombosis (cPVT). These vascular changes often occur in the setting of non-cirrhotic, non-neoplastic portal hypertension. Its prevalence among cPVT patients ranges from 4% to 92%, with an unweighted average of 45.2%, increasing to 67.0% in studies using magnetic resonance cholangiopancreatography (MRCP) or endoscopic retrograde cholangiopancreatography (ERCP). Although most patients remain asymptomatic, about 25% develop symptoms. Diagnosis mainly depends on imaging, with MRCP being the most accurate choice. The classification proposed by Llop and colleagues provides a useful framework by integrating anatomical involvement with the severity of biliary disease. However, combining this classification with the pathophysiological one could support a more personalized treatment approach. Management depends on symptom presentation. Asymptomatic patients are managed conservatively. Symptomatic cases may require endoscopic interventions; plastic stents are most commonly used, although they have around a 30% risk of hemobilia and a high re-intervention rate of ~50%. Interventional radiology techniques, particularly portal vein recanalization with transjugular intrahepatic portosystemic shunt (TIPS), exhibit high technical success rates (median 91%) and patency rates (median 81.8%). Surgical portosystemic shunts remain a key option for a subgroup of patients, with about 65% achieving symptom resolution after decompression alone, whereas liver transplantation is rarely indicated. Given the rarity of this condition and the limited quality of existing studies, we conducted this systematic review to provide a comprehensive overview of the current literature and to promote a more standardized approach to managing PCC. This review aims to fill knowledge gaps and enhance consistency in treatment strategies for this complex condition.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.